In vivo evaluation of antibiotic activity against Mycobacterium abscessus

Journal of Infectious Diseases

Volumn 209, Issue 6, 2014, Pages 905-912

  Lerat, Isabelle ^a   Cambau, Emmanuelle ^c,d   Roth Dit Bettoni, Romain ^a   Gaillard, Jean Louis ^e,f   Jarlier, Vincent ^a,b   Truffot, Chantal ^a   Veziris, Nicolas ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b Laboratoire de Bactériologie Hygiène Hôpital Pitié Salpêtrière Ctr Natl de Reference des Mycobacteries et de la Resistance des Mycobacteries Aux Antituberculeux   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

Author keywords

amikacin; bedaquiline; cefoxitin; clarithromycin; cystic fibrosis; murine model; Mycobacterium abscessus; nude mouse; tigecycline; TMC207

Indexed keywords

AMIKACIN; BEDAQUILINE; CEFOXITIN; CLARITHROMYCIN; TIGECYCLINE;

A J MOUSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; BAGG ALBINO MOUSE; C57BL 6 MOUSE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; MOUSE MODEL; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM ABSCESSUS INFECTION; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPLEEN; SWISS WEBSTER MOUSE;

AMIKACIN; BEDAQUILINE; CEFOXITIN; CLARITHROMYCIN; CYSTIC FIBROSIS; MURINE MODEL; MYCOBACTERIUM ABSCESSUS; NUDE MOUSE; TIGECYCLINE; TMC207;

ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DIARYLQUINOLINES; DISEASE MODELS, ANIMAL; FEMALE; KIDNEY; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; SPLEEN; STATISTICS, NONPARAMETRIC;

EID: 84895748391     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit614     Document Type: Article

References (48)

1. Adékambi T, Berger P, Raoult D, Drancourt M. rpoB gene sequencebased characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006; 56:133-43.
2. Adékambi T, Reynaud-Gaubert M, Greub G, et al. Amoebal coculture of 'Mycobacterium massiliense' sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 2004; 42:5493-501.
3. Esther CR Jr, Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9:117-23.
4. Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C, et al. Mycobacterium abscessus and children with cystic fibrosis. Emerging Infect Dis 2003; 9:1587-91.
5. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients. Am Rev Respir Dis 1993; 147:1271-8.
6. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416.
7. Garrison AP, Morris MI, Doblecki Lewis S, et al. Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature. Transpl Infect Dis 2009; 11:541-8.
8. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38:1428-39.
9. Leao SC, Tortoli E, Viana-Niero C, et al. Characterization of mycobacteria from a major Brazilian outbreak suggests that revision of the taxonomic status of members of the Mycobacterium chelonae-M. abscessus group is needed. J Clin Microbiol 2009; 47:2691-8.
10. Viana-Niero C, Lima KVB, Lopes ML, et al. Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol 2008; 46:850-5.
11. Van Ingen J. Strategies to improve outcome of drug treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52:1281-2.
12. Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180:896-902.
13. Brown-Elliott BA, Nash KA, Wallace RJ. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 2012; 25:545-82.
14. Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011; 183:405-10.
15. Kim HS, Lee KS, Koh WJ, et al. Serial CT findings of Mycobacterium massiliense pulmonary disease compared with Mycobacterium abscessus disease after treatment with antibiotic therapy. Radiology 2012; 263:260-70.
16. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012; 67:810-8.
17. Adékambi T, Drancourt M. Mycobacterium bolletii respiratory infections. Emerging Infect Dis 2009; 15:302-5.
18. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS ONE 2011; 6:e17556.
19. Ji B, Chauffour A, Robert J, Lefrançois S, Jarlier V. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2007; 51:3737-9.
20. Bermudez LE, Kolonoski P, Young LS, Inderlied CB. Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrob Agents Chemother 1994; 38:1844-8.
21. Bermudez LE, Nash KA, Petrofsky M, Young LS, Inderlied CB. Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model. J Infect Dis 1996; 174: 1218-22.
22. Lepeule R, Ruppé E, Le P, et al. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli Harboring CTX-M-15-type extended-spectrum α-lactamase. Antimicrob Agents Chemother 2012; 56:1376-81.
23. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006; 50:3543-7.
24. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223-7.
25. Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP. Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob Agents Chemother 2009; 53:5060-3.
26. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005; 41:S333-40.
27. Lounis N, Gevers T, Van Den Berg J, Verhaeghe T, van Heeswijk R, Andries K. Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207. J Clin Microbiol 2008; 46: 2212-5.
28. Ordway D, Henao-Tamayo M, Smith E, et al. Animal model of Mycobacterium abscessus lung infection. J Leukoc Biol 2008; 83:1502-11.
29. Lounis N, Ji B, Truffot-Pernot C, Grosset J. Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. Antimicrob Agents Chemother 1997; 41:1168-9.
30. Atkinson BA, Bocanegra R, Graybill Jr. Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. Antimicrob Agents Chemother 1995; 39:2316-9.
31. Ji B, Perani EG, Petinon C, Grosset JH. Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice. Int J Lepr Other Mycobact Dis 1992; 60:556-61.
32. Andréjak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH. Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. J Antimicrob Chemother 2013; 68:659-65.
33. Heifets LB, Lindholm-Levy PJ, Comstock RD. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis 1992; 145:856-8.
34. Bastian S, Veziris N, Roux AL, et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55:775-81.
35. Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and M. massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186:917-25.
36. Greendyke R, Byrd TF. Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. Antimicrob Agents Chemother 2008; 52: 2019-26.
37. Choi WS, Kim MJ, Park DW, et al. Clarithromycin and amikacin vs. clarithromycin and moxifloxacin for the treatment of post-acupuncture cutaneous infections due to Mycobacterium abscessus: a prospective observational study. Clin Microbiol Infect 2011; 17:1084-90.
38. Lavollay M, Fourgeaud M, Herrmann JL, et al. The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by L,D-transpeptidases. J Bacteriol 2011; 193:778-82.
39. Mainardi JL, Hugonnet JE, Rusconi F, et al. Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the ?- lactam imipenem. J Biol Chem 2007; 282:30414-22.
40. Lavollay M, Arthur M, Fourgeaud M, et al. The peptidoglycan of stationary- phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation. J Bacteriol 2008; 190: 4360-6.
41. Miyasaka T, Kunishima H, Komatsu M, et al. In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus. Int J Antimicrob Agents 2007; 30:255-8.
42. Choi GE, Min KN, Won CJ, Jeon K, Shin SJ, Koh WJ. Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. Antimicrob Agents Chemother 2012; 56:3549-55.
43. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46:3164-7.
44. Huang CW, Chen JH, Hu ST, et al. Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in Taiwan. Int J Antimicrob Agents 2013;41:218-23.
45. Vardakas KZ, Rafailidis PI, Falagas ME. Effectiveness and safety of tigecycline: focus on use for approved indications. Clin Infect Dis 2012; 54:1672-4.
46. Lounis N, Gevers T, Van Den Berg J, Vranckx L, Andries K. ATP synthase inhibition of Mycobacterium avium Is not bactericidal. Antimicrob Agents Chemother 2009; 53:4927-9.
47. van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother 2012; 56:6324-7.
48. Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010; 35:400-4.